What is hyposomatotropism (growth hormone deficiency [GHD])?

Updated: Jan 24, 2019
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print
Answer

Hyposomatotropism is a deficiency in the release of pituitary growth hormone (somatotropin), resulting in short stature. Achievement of final adult height consistent with a child's genetic potential remains the primary therapeutic endpoint for recombinanat human growth hormone (rhGH) therapy in the pediatric population. In addition to its effects on bone mass, GH regulates muscle mass, muscular strength, body composition, lipid and carbohydrate metabolism, and cardiac function. Patients with growth hormone deficiency (GHD) typically have hyperlipidemia, increased body fat, premature atherosclerotic plaques, delayed bone maturation, and impaired cardiac function.  [1, 2, 3, 4, 5, 6, 7, 8, 9]

GHD in adults is recognized as a distinct clinical syndrome that encompasses reduced psychological well-being and specific metabolic abnormalities. Such abnormalities, including hypertension, central obesityinsulin resistance, dyslipidemia, and coagulopathy, closely resemble those of metabolic insulin resistance syndrome. [10] The increased rates of cardiovascular morbidity and mortality reinforce the close association between the syndromes. [11]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!